Psoriatic Arthritis
Conference Coverage
Study highlights need to investigate psoriasis treatment outcomes in skin of color patients
MIAMI – Researchers used phase 2 and 3 psoriasis clinical trial data to explore potential differences in treatment response in various ethnic...
Conference Coverage
2017 was a big year for psoriatic arthritis
MAUI, HAWAII – “There is a tremendous amount of excitement now in the field of psoriatic arthritis.” – Arthur Kavanaugh, MD.
News
Xeljanz: FDA panel recommends ulcerative colitis indication
SILVER SPRING, MD. – Federal advisors to the FDA on March 8 voted unanimously to recommend approval of tofacitinib (Xeljanz) for ulcerative...
Conference Coverage
Psoriatic arthritis treatment: “We’re not doing so well”
MAUI, HAWAII – “Psoriatic arthritis lags behind rheumatoid arthritis, maybe by a decade,” despite current treatments and a treat-to-target...
Clinical Review
Do Psoriasis Patients Engage In Vigorous Physical Activity?
Psoriasis is associated with cardiovascular risk factors and myocardial infarction, but regular physical activity is known to decrease the risk of...
Conference Coverage
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
SAN DIEGO - The idea behind starting PPACMAN the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Networkwas to form clinics at...
Conference Coverage
Could guselkumab be a disease-modifying agent in plaque psoriasis?
SAN DIEGO – Questions remain about why some patients maintain durable response.
Conference Coverage
Ustekinumab quells aortic inflammation in patients with severe psoriasis
SAN DIEGO – The benefit may be a class-associated effect.
From the Journals
Biologics have best chance of achieving PASI 90 in psoriasis
Results derived from a meta-analysis of 109 randomized, controlled trials contrast with real-world treatment recommendations.
Conference Coverage
Risankizumab outpaced ustekinumab for complete clearance of plaque psoriasis
Latest News
Here comes bimekizumab, the newest IL-17 inhibitor
KAUAI, HAWAII – “If this holds up in phase 3, it’s going to be a new world for our patients and for us, ” said Craig L. Leonardi, MD.